Oncology Co. Receives Buy Rating for New Drug Trials
Source: Dr. Joseph Pantginis  (4/18/23)
A California drug company is moving into new phases of drug trials targeted at solid tumors, noted an H.C.Wainwright & Co. report. More >

Biotech Rated Outperform Advances Top Drug Candidate
Source: Dr. David Nierengarten  (4/18/23)
The biotech launches another trial of its KIT inhibitor and reports preclinical data for other inhibitors in its pipeline, noted a Wedbush report. More >

Trial Results of New Pneumococcal Vaccine Compelling
Source: Dr. Thomas Shrader   (4/18/23)
Data show the vaccine elicited better immune responses in adults ages 50 and up than the standard of care vaccine, noted a BTIG report. More >

Follow-up Results From T2 Diabetes Trial Positive
Source: Dr. Jonathan Aschoff   (4/14/23)
One year out, overall efficacy was 93% in the patients treated with a new autologous immunotherapy, noted a ROTH Capital Partners report. More >

Biotech Co. Set To Reach New Highs
Source: Streetwise Reports  (4/13/23)
Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics. More >

Phase 3 Trial in Progress of New Ichthyosis Treatment
Source: Dr. Ram Selvaraju  (4/12/23)
Patient recruitment is 50% complete for this multicenter study evaluating a designated orphan drug as treatment for these congenital disorders, noted an H.C. Wainwright & Co. report. More >

Phase 2b Trial of New Drug for Ovarian Cancer Starts
Source: Dr. Joseph Pantginis   (4/11/23)
The investigative, novel small molecule is the lead drug candidate for this U.S. biopharma developing treatments for serious oncological conditions of unmet medical need, noted an H.C. Wainwright & Co. report. More >

Safety Data From One Trial of New Drug Helpful to Another
Source: Ed Arce  (4/5/23)
The investigative compound is atrasentan, currently under evaluation in a Phase 3 study as a treatment for nephropathy, noted an H.C. Wainwright & Co. report. More >

Biotech Co. Will 'Not Look Back' From Here
Source: Clive Maund  (4/5/23)
In light of its recent development of a product that purportedly has the ability to reset damaged DNA, technical analyst Clive Maund takes a look at Resverlogix Corp. More >

Target Price on Texas-Based Drug Co. Implies 1,929% ROI
Source: Dr. Jonathan Aschoff   (4/4/23)
This biopharma expects two major catalysts, in the form of Phase 2 clinical trial data readouts, this year, noted a ROTH Capital Partners report. More >

Resverlogix Testing Cure for Covid, the Terrible Spike Protein and Heart Issues
Source: Bob Moriarty  (4/3/23)
In light of Resverlogix Corp.'s testing of a cure for long Covid, Bob Moriarty of 321gold.com reviews the company to tell you why he believes it may be a Buy. More >

New Treatment for Ovarian Cancer Shows Promise
Source: Emily Bodnar  (3/30/23)
Additional trial data also show efficacy of this investigative combination treatment in a difficult to treat patient population, noted an H.C. Wainwright & Co. report. More >

Coverage Launched on Drug Co. With 140% Upside
Source: Stefan Quenneville  (3/29/23)
The Canadian specialty pharma, with a proven track record of in-licensing and acquiring late-stage assets, is "poised to grow meaningfully in the coming years," noted an Echelon Capital Markets report. More >

Trial of New Ophthalmic Drug Now Enrolled
Source: Dr. Yi Chen  (3/29/23)
More than the target number of patients was enrolled in this Phase 2 study of an investigative treatment for a serious eye disease, noted an H.C. Wainwright & Co. report. More >

FDA Approval of New Gout Drug Likely, Analyst Says
Source: Yun Zhong  (3/27/23)
Despite a competitor already on the market, the commercial opportunity for this particular treatment is strong, given its advantages, noted a BTIG report. More >

Biotech Improves Efficiency of Its New Immunotherapy
Source: Dr. Jonathan Aschoff  (3/22/23)
The enhancements the company made to its investigative therapy that uses a patient's own immune cells were independently validated, noted a ROTH research report. More >

Former NFL Safety Director Joins Neurotherapy Firm Advisory Board
Source: Streetwise Reports  (3/21/23)
Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody. More >

Coverage Launched on Canadian Specialty Pharma Co.
Source: Stefan Quenneville  (3/15/23)
This company can further grow its product portfolio and revenues and, thus, boost its operating leverage, but these capabilities "remain underappreciated by investors," noted an Echelon Capital Markets report. More >

New Skin Gene Therapy Gets PDUFA Date
Source: Dr. Joseph Pantginis  (3/1/23)
The future of this investigational treatment for dystrophic epidermolysis bullosa looks positive, with full approval and subsequent successful commercial launch expected, noted an H.C. Wainwright & Co. report. More >

Novel Therapy Corp Captures More of US Licensing Market, First EU Segment
Source: Streetwise Reports  (2/28/23)
White-label reselling of proven therapeutic compounds and concepts to existing, branded providers offers research companies a way to capture market share without marketing expenses – or other customer-facing costs. Awakn Life Sciences Corp., already a marquee name in rehabilitation clinics across Europe, is also rapidly engaging in this lucrative secondary profit stream. More >

Biotech Co. Initiates Feasibility Study
Source: Streetwise Reports  (2/9/23)
This morning Awakn Life Sciences announced it had initiated a feasibility study of MDMA leveraging Catalent's proprietary Zydis ODT fast dissolve technology. Read more to learn what this means for the company, why this may be needed, and what experts are saying about Awakn.  More >

New Drug for Hearing Loss Approved for Clinical Trials
Source: Dr. Joseph Pantginis  (1/30/23)
Plans call for an initial clinical trial to start in H1/23 in both the U.S. and the United Kingdom, where the biopharma recently received approval to proceed, noted an H.C. Wainwright & Co. report. More >

Biopharma Gains Another Shot on Goal With IND Approval
Source: Edward White   (1/26/23)
The firm's CD19- and CD3-targeting monoclonal antibody is now cleared for evaluation in a Phase I clinical trial, noted an H.C. Wainwright & Co. report. More >

Biopharma Creating COVID Drug Gets US$8.2M From the DOD
Source: Edward White  (1/24/23)
This tranche, other cash and cash equivalents, and current cash flow are sufficient to get the developer of immunotherapeutics through 2023, noted an H.C. Wainwright & Co. report. More >

Biotech's Novel Thin Formulation Improves Veteran-Aiding Treatment
Source: Streetwise Reports  (1/24/23)
Awakn Life Sciences announced further details regarding its August 2022 announcement that it had "signed a twelve-month option agreement with a leading drug development, manufacturing, and delivery systems company to in-license a proprietary formulation and route of administration for ketamine." Read to learn more about this announcement, the benefits of this treatment, and what analysts and experts are saying about the company. More >